CVRx (NASDAQ:CVRX – Get Rating) is one of 213 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare CVRx to related companies based on the strength of its risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
Earnings and Valuation
This table compares CVRx and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|CVRx||$13.04 million||-$43.08 million||-0.11|
|CVRx Competitors||$1.15 billion||$84.78 million||-482.42|
Insider and Institutional Ownership
65.9% of CVRx shares are held by institutional investors. Comparatively, 50.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 14.1% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent ratings for CVRx and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CVRx presently has a consensus price target of $20.84, indicating a potential upside of 294.77%. As a group, “Surgical & medical instruments” companies have a potential upside of 56.47%. Given CVRx’s stronger consensus rating and higher possible upside, research analysts clearly believe CVRx is more favorable than its rivals.
This table compares CVRx and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About CVRx (Get Rating)
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.